Gram-positive bacteria

First Light Biosciences Develops Rapid Test for C. Difficile Toxin B. in Stool Samples

Retrieved on: 
Wednesday, November 28, 2018
Bacteria, Bacterial toxins, Gram-positive bacteria, Clostridium difficile infection, Diarrhea, RTT, Clostridioides difficile, Clostridium difficile toxin B, C. Diff, Infection, Antimicrobial resistance, Clostridium difficile

For this reason, C. difficile is the top pathogen on CDC's list of Urgent Threats.

Key Points: 
  • For this reason, C. difficile is the top pathogen on CDC's list of Urgent Threats.
  • "We were pleased to have the opportunity to present the results of our rapid,ultrasensitive MultiPath CDI test at the ASM Microbe conference this year,"said David Macdonald, CEO of First Light Biosciences.
  • View the poster A Rapid Single Molecule Counting Method Sensitively Detects Clostridium difficile Toxin B Directly in Stool Samples.
  • First Light Biosciences is developing and preparing to commercialize, innovative diagnostic products for rapid, sensitive and cost-saving detection of life-threatening infections, and for combating the spread of antibiotic resistance.

First Light Biosciences Announces Peer-Reviewed Publication

Retrieved on: 
Thursday, October 25, 2018
Bacteria, Clostridiaceae, Gram-positive bacteria, Clostridium difficile infection, Diarrhea, RTT, C. Diff, Clostridioides difficile, Clostridium, CDI

The paper presents results demonstrating the performance of First Light's rapid test for Clostridium difficileinfection (CDI) using the company's novel MultiPath digital imaging technology.

Key Points: 
  • The paper presents results demonstrating the performance of First Light's rapid test for Clostridium difficileinfection (CDI) using the company's novel MultiPath digital imaging technology.
  • "We are pleased with the results of our C. difficile study," said David Macdonald, CEO of First Light Biosciences.
  • This peer-reviewed publication offers compelling evidence that the MultiPath test provides superior accuracy."
  • This will improve patient outcomes, reduce healthcare costs, and prevent inappropriate use of powerful antibiotics.To learn more, please visit: www.firstlightibio.com .

AixSwiss promotes the importance of gut health by providing American consumers with Nupure Probiflor

Retrieved on: 
Wednesday, August 29, 2018
Bacteria, Gram-positive bacteria, Bacteriology, Lactobacillaceae, Streptococcaceae, Dietary Supplements, Streptococcus thermophilus, Bifidobacterium, Lactobacillales, Dietary fiber, Lactic acid, Lactobacillus

Nupure Probiflor is one of the products in the line, consisting of 11 bacterial cultures.

Key Points: 
  • Nupure Probiflor is one of the products in the line, consisting of 11 bacterial cultures.
  • Nupure Probiflor is an immune complex consisting of three strains of bifidobacteria, seven strains of lactobacilli (lactic acid bacteria), and Streptococcus thermophilus.
  • The 11 bacterial strains are perfectly coordinated and cover a broad spectrum of the natural, healthy intestinal floor.
  • Inulin is a fiber that is not metabolized by humans; however, it promotes the optimal growth of important bacterial cultures in the gut.

IVD Industry Battles AMR, Touts Biotin-Free Immunoassays and Smaller Footprints at the 2018 American Association for Clinical Chemistry Meeting

Retrieved on: 
Thursday, August 2, 2018
Bacteria, Clostridiaceae, Gram-positive bacteria, C. Diff, Diarrhea, Clostridium difficile, Clostridium, Infection

Close to 250,000 people are hospitalized every year for a Clostridium difficile (C. difficile) infection, and 14,000 of them die.

Key Points: 
  • Close to 250,000 people are hospitalized every year for a Clostridium difficile (C. difficile) infection, and 14,000 of them die.
  • Roche Diagnostics highlighted their Liat systems that can quickly assess flu or strep, and thus reduce unnecessary treatment.
  • The company, a member of the AMR Industry Alliance, displayed its BacT/Alert Virtuo at the meeting.
  • BacT/Alert Virtuo is an advanced, automated blood culture system incorporating improved automation and an enhanced detection algorithm to shorten time to detection.

FDA Grants QIDP Designation to Acurx's Lead Antibiotic Product Candidate, ACX-362E for Clostridium Difficile Infection

Retrieved on: 
Wednesday, June 20, 2018
Bacteria, Clostridiaceae, Gram-positive bacteria, Diarrhea, Antibiotics, Clostridium difficile infection, RTT, Clostridium difficile, Clostridium, Food and Drug Administration, Lipoglycopeptide

The QIDP designation was granted by the FDA for the treatment of patients with Clostridium difficile infection (CDI).

Key Points: 
  • The QIDP designation was granted by the FDA for the treatment of patients with Clostridium difficile infection (CDI).
  • Under QIDP designation, ACX-362E will now be eligible to benefit from certain incentives for the development of new antibiotics provided under the Generating Antibiotic Incentives Now Act (the GAIN Act).
  • Further, if ultimately approved by the FDA, ACX-362E is eligible for an additional five-year extension of Hatch-Waxman marketing exclusivity.
  • The CDC (Centers for Disease Control & Prevention) has designated Clostridium difficile bacteria as an urgent threat highlighting the need for new antibiotics to treat CDI.

Frequently Enjoying Kimchi Decreases Body Fat and Suppresses Obesity-Related Complications

Retrieved on: 
Thursday, June 14, 2018
Bacteria, Food and drink, Lactobacillaceae, Garde manger, Obesity, Lactobacillales, Gram-positive bacteria, Lactobacillus, Diet-induced obesity model, Lactic acid, Kimchi, Adipose tissue

In his recent study, Dr. Hak-Jong Choi and his team at the World Institute of kimchi found that, after the high fat diet-induced obese mice were fed Lactobacillus sakei, which were isolated from kimchi, fat cell differentiation was suppressed and the percentage of body fat decreased.

Key Points: 
  • In his recent study, Dr. Hak-Jong Choi and his team at the World Institute of kimchi found that, after the high fat diet-induced obese mice were fed Lactobacillus sakei, which were isolated from kimchi, fat cell differentiation was suppressed and the percentage of body fat decreased.
  • Dr. Kim's research titled, "Lactic Acid Bacteria Isolated from Kimchi to Evaluate Anti-obesity Effects in High Fat Diet-induced Obese Mice," was published in the latest issue (March 2018, Vol.
  • Dr. Kim said, "The two strains of lactic acid bacteria derived from kimchi helped relieve a number of obesity-related symptoms."
  • According to Dr. Choi of WiKim, "Kimchi's effect on reducing body fat and suppressing obesity-related complications is thanks to roughly 200 types of lactic acid bacteria found in kimchi including Lactobaccilius, Leuconostoc, Weissella."

Frequently Enjoying Kimchi Decreases Body Fat and Suppresses Obesity-Related Complications

Retrieved on: 
Thursday, June 14, 2018
Bacteria, Food and drink, Lactobacillaceae, Garde manger, Obesity, Lactobacillales, Gram-positive bacteria, Lactobacillus, Diet-induced obesity model, Lactic acid, Kimchi, Adipose tissue

In his recent study, Dr. Hak-Jong Choi and his team at the World Institute of kimchi found that, after the high fat diet-induced obese mice were fed Lactobacillus sakei, which were isolated from kimchi, fat cell differentiation was suppressed and the percentage of body fat decreased.

Key Points: 
  • In his recent study, Dr. Hak-Jong Choi and his team at the World Institute of kimchi found that, after the high fat diet-induced obese mice were fed Lactobacillus sakei, which were isolated from kimchi, fat cell differentiation was suppressed and the percentage of body fat decreased.
  • Dr. Kim's research titled, "Lactic Acid Bacteria Isolated from Kimchi to Evaluate Anti-obesity Effects in High Fat Diet-induced Obese Mice," was published in the latest issue (March 2018, Vol.
  • Dr. Kim said, "The two strains of lactic acid bacteria derived from kimchi helped relieve a number of obesity-related symptoms."
  • According to Dr. Choi of WiKim, "Kimchi's effect on reducing body fat and suppressing obesity-related complications is thanks to roughly 200 types of lactic acid bacteria found in kimchi including Lactobaccilius, Leuconostoc, Weissella."

Rebiotix Microbiota Restoration Therapy™ Products, Microbiome Health Index™ to Take Center Stage at Digestive Disease Week 2018

Retrieved on: 
Monday, June 4, 2018
Bacteria, Clostridiaceae, Gram-positive bacteria, Diarrhea, C. Diff, Clostridium difficile, Clostridium, Infection, Breakthrough therapy, Fecal microbiota transplant, Antibiotic-associated diarrhea

Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff)infection.

Key Points: 
  • Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff)infection.
  • RBX2660 has been granted Fast Track status, Orphan Drug and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection.
  • In addition, Rebiotix is targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy platform.
  • Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women's health, and in specialty areas within gastroenterology and urology.

Pain Clinic Class Action Certified (Law Firm: Harte Law PC)

Retrieved on: 
Monday, May 28, 2018
Bacteria, Perception, Microbiology, Bacteriology, Gram-positive bacteria, Pathogenic bacteria, Staphylococcus aureus, Pain, Injection

These individuals received pain injections performed by Dr. James at the Rothbart Centre for Pain Care Ltd. over a two-year period starting on January 1, 2010.

Key Points: 
  • These individuals received pain injections performed by Dr. James at the Rothbart Centre for Pain Care Ltd. over a two-year period starting on January 1, 2010.
  • Members of the class are represented by the law firm Harte Law PC.
  • The lawsuit alleges that Dr. James performed the injections at the pain clinic without adequate infection control, infecting certain patients with Staph aureus.
  • In addition to Dr. James, the lawsuit names the pain clinic, clinic director Peter Rothbart and a number of nurses who worked at the Clinic.